Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

130
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
130
Analgesia and Pain Management01:25

Analgesia and Pain Management

632
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
632
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

305
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
305
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

168
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
168
Local Anesthetics: Clinical Application as Spinal Anesthesia01:11

Local Anesthetics: Clinical Application as Spinal Anesthesia

639
Spinal anesthetics are given during lower abdomen and limb surgeries to block sensory and motor neurons. They are administered in the mid to low lumbar regions, primarily acting on the cauda equina's nerve roots. The blockade level depends on the local anesthetic (LA) concentration. Usually, low LA concentrations are sufficient to block sensory fibers, while only high LA concentrations block motor fibers. Other factors like injection volume and speed, the patient's posture, and the drug...
639
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

179
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
179

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postmenopausal Osteoporosis, Endothelial Dysfunction, and Cardiovascular Risk.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same author

Relationship Between Central Sensitization and Genetic Polymorphisms-A Case-Control Study in Fibromyalgia.

European journal of pain (London, England)·2026
Same author

Bioavailable human metabolites of a keratin-derived hydrolysate promote primary human dermal fibroblast activities and protect against oxidative stress-related damages.

Frontiers in nutrition·2026
Same author

Increasing plant protein sources in the diet modulates gut microbiota and tryptophan metabolism in men at cardiometabolic risk.

Gut microbes·2026
Same author

The complexity of pain in osteoarthritis.

Nature reviews. Rheumatology·2026
Same author

A European Delphi Consensus to Support the Diagnosis, Management, and Appropriate Positioning of Topical Treatments for Postherpetic Neuralgia (PHN).

Pain and therapy·2026
Same journal

[Oxytocin versus dopamine: The delicate balance between social bonding and addiction].

Biologie aujourd'hui·2026
Same journal

[Vocal learning and cognition in oscine songbirds: a model for studying the biological basis of language].

Biologie aujourd'hui·2026
Same journal

[Art, mourning, and culture: New frontiers in primate cognition].

Biologie aujourd'hui·2026
Same journal

[Reinforcing the mind-muscle connection: Mental Imagery as a tool for strength enhancement in athletes].

Biologie aujourd'hui·2026
Same journal

[Popular myths vs. physiological realities: The rehabilitation of lactate].

Biologie aujourd'hui·2026
Same journal

Biologie aujourd'hui·2025
See all related articles

Related Experiment Video

Updated: Jul 9, 2025

Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.3K

[Ketamine in chronic pain].

Gisèle Pickering1

  • 1Plateforme d'Investigation Clinique / Centre d'Investigation Clinique Inserm 1405 - CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France - Laboratoire Neuro-Dol Inserm 1107, Université Clermont Auvergne, 63000 Clermont-Ferrand, France.

Biologie Aujourd'Hui
|November 29, 2023
PubMed
Summary
This summary is machine-generated.

Ketamine shows promise for chronic pain but requires further research. Optimizing its use involves personalized approaches considering pain type and patient psychology for better outcomes.

Keywords:
adverse effectschronic paindouleur chroniqueeffets indésirablesefficacitéefficacyketaminekétamine

More Related Videos

Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

9.5K
Author Spotlight: Unveiling the Therapeutic Effects of FSN Treatment – Bridging Research and Clinical Applications in Neuropathic Pain
08:20

Author Spotlight: Unveiling the Therapeutic Effects of FSN Treatment – Bridging Research and Clinical Applications in Neuropathic Pain

Published on: June 30, 2023

2.0K

Related Experiment Videos

Last Updated: Jul 9, 2025

Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.3K
Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

9.5K
Author Spotlight: Unveiling the Therapeutic Effects of FSN Treatment – Bridging Research and Clinical Applications in Neuropathic Pain
08:20

Author Spotlight: Unveiling the Therapeutic Effects of FSN Treatment – Bridging Research and Clinical Applications in Neuropathic Pain

Published on: June 30, 2023

2.0K

Area of Science:

  • Anesthesiology and Pain Management
  • Pharmacology
  • Clinical Neuroscience

Context:

  • Ketamine is increasingly utilized for chronic pain unresponsive to standard therapies.
  • Existing literature presents variable efficacy and adverse effects due to diverse study designs and administration methods.
  • This has led to ongoing debate about ketamine's true clinical value in pain management.

Purpose:

  • To address the need for larger, well-selected patient cohorts and real-world studies on ketamine for chronic pain.
  • To refine ketamine's prescription dosages and elucidate its long-term adverse effects.
  • To improve recommendations for ketamine use by considering pain etiology and patient psycho-affective profiles.

Summary:

  • Recent advancements include improved recommendations for ketamine use in chronic pain.
  • These recommendations acknowledge varied analgesic responses based on pain type and patient psychological factors.
  • A comprehensive strategy integrating pain and depression management is essential for optimal ketamine therapy.

Impact:

  • Enhanced understanding of ketamine's efficacy and safety profile in chronic pain management.
  • Development of more precise and personalized ketamine treatment protocols.
  • Improved patient outcomes through a holistic approach to pain and comorbid conditions like depression.